Insulin icodec + semaglutide

1. Insulin icodec + semaglutide decreases LDL cholesterol in humans (ETR 0.94, 95% CI 0.90-0.98).

   Human trialin patients with type 2 diabetes inadequately controlled on basal insulinn = 1,970

   Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trials · Cardiovascular diabetology. Endocrinology reports · 2 Sep 2026

LDL cholesterol →

1. Insulin icodec + semaglutide has no effect on HbA1c in humans (pooled MD -0.37%, 95% CI -0.95 to 0.21).

   Human trialin patients with type 2 diabetes inadequately controlled on basal insulinn = 1,970

   Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trials · Cardiovascular diabetology. Endocrinology reports · 2 Sep 2026

HbA1c →

1. Insulin icodec + semaglutide decreases systolic blood pressure in humans (MD -2.45 mmHg, 95% CI -3.52 to -1.38).

   Human trialin patients with type 2 diabetes inadequately controlled on basal insulinn = 1,970

   Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trials · Cardiovascular diabetology. Endocrinology reports · 2 Sep 2026

1. Insulin icodec + semaglutide decreases body weight in humans (pooled MD -6.10 kg, 95% CI -7.21 to -5.00).

   Human trialin patients with type 2 diabetes inadequately controlled on basal insulinn = 1,970

   Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trials · Cardiovascular diabetology. Endocrinology reports · 2 Sep 2026